249 related articles for article (PubMed ID: 18823024)
1. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M;
Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
[TBL] [Abstract][Full Text] [Related]
3. Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Nio Y; Toga T; Maruyama R; Fukushima M
Oncol Rep; 2007 Jul; 18(1):59-64. PubMed ID: 17549346
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
5. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Nakamori S; Endo W; Ozato H; Shibata T; Takeda Y; Tohno K; Hasuike Y; Masutani S; Morimoto T; Doki Y; Mori M; Monden M
Gan To Kagaku Ryoho; 2011 May; 38(5):789-92. PubMed ID: 21566438
[TBL] [Abstract][Full Text] [Related]
6. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
Haas M; Waldschmidt DT; Stahl M; Reinacher-Schick A; Freiberg-Richter J; Fischer von Weikersthal L; Kaiser F; Kanzler S; Frickhofen N; Seufferlein T; Dechow T; Mahlberg R; Malfertheiner P; Illerhaus G; Kubicka S; Abdul-Ahad A; Snijder R; Kruger S; Westphalen CB; Held S; von Bergwelt-Baildon M; Boeck S; Heinemann V
Eur J Cancer; 2021 Mar; 146():95-106. PubMed ID: 33588150
[TBL] [Abstract][Full Text] [Related]
7. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Nio Y; Hashimoto K; Yano S; Itakura M; Koike M; Yamaguchi K; Endo S; Tsuji M; Higami T; Maruyama R
Oncol Rep; 2005 Aug; 14(2):401-8. PubMed ID: 16012722
[TBL] [Abstract][Full Text] [Related]
8. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
10. [Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
Sumii T; Funakoshi A; Mizumoto K; Tanaka M; Arita Y; Ito T; Yamaguchi H; Ueki T; Sakai T; Miyahara T; Muranaka T; Igarashi H; Shinozaki H; Eriguchi N
Gan To Kagaku Ryoho; 2008 Apr; 35(4):603-6. PubMed ID: 18408428
[TBL] [Abstract][Full Text] [Related]
11. [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Nakamori S; Tujie M; Takahashi Y; Maruhashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Gan To Kagaku Ryoho; 2004 Jan; 31(1):51-4. PubMed ID: 14750321
[TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
[TBL] [Abstract][Full Text] [Related]
14. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
15. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Tatarian T; Jiang W; Leiby BE; Grigoli A; Jimbo M; Dabbish N; Neoptolemos JP; Greenhalf W; Costello E; Ghaneh P; Halloran C; Palmer D; Buchler M; Yeo CJ; Winter JM; Brody JR
Ann Surg; 2018 Feb; 267(2):364-369. PubMed ID: 27893535
[TBL] [Abstract][Full Text] [Related]
18. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
